Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Aurinia Pharm Ord (NQ: AUPH ) 7.210 -0.150 (-2.04%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 825,179 Open 7.370 Bid (Size) 7.120 (1) Ask (Size) 7.400 (13) Prev. Close 7.360 Today's Range 7.210 - 7.390 52wk Range 4.710 - 9.740 Shares Outstanding 128,395,927 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024 October 30, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis September 24, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Performance YTD -17.51% -17.51% 1 Month -1.64% -1.64% 3 Month +22.62% +22.62% 6 Month +38.65% +38.65% 1 Year -1.77% -1.77% More News Read More Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference September 13, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Aurinia Announces Board Restructuring September 12, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial September 05, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference August 28, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results August 01, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024 July 19, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Aurinia to Participate in Upcoming Investor Healthcare Conferences July 02, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Aurinia Announces 2024 Annual General Meeting Results June 14, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024 June 05, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce June 04, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Aurinia Provides Update on Proxy Statement June 03, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Aurinia Will Attend 2024 Jefferies Global Healthcare Conference May 30, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024 May 14, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024 May 09, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference May 07, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire AUPH Stock Earnings: Aurinia Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 May 02, 2024 Via InvestorPlace Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results May 02, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month May 01, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program April 30, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference April 16, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024 April 15, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference April 09, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program February 29, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
